Blood distribution and single–dose pharmacokinetics of leflunomide

Therapeutic Drug Monitoring

Volumn 17, Issue 5, 1995, Pages 454-459

  Lucien, Jamie ^a   Dias, Valerian C ^a   LeGatt, Donald F ^a   Yatscoff, Randall W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

A77 1726; Blood distribution; Hwa 486; Leflunomide; Leflunomide metabolite; Pharmacokinetics

Indexed keywords

LEFLUNOMIDE; TERIFLUNOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RABBIT; T LYMPHOCYTE ACTIVATION;

ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMAL; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; HALF-LIFE; HYDROXYBUTYRATES; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; ISOXAZOLES; LIPOPROTEINS; RABBITS; ULTRACENTRIFUGATION;

EID: 0029122535     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/00007691-199510000-00004     Document Type: Article

References (24)

1. Bartlett RR, Dimitrijevic M, Mattar T, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of auto immune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10.
2. Morris RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993;12:275.
3. Chong AS-F, Finnegan A, XingLi J, et al. Leflunomide, a novel immunosuppressive agent: The mechanism of inhibition of T cell proliferation. Transplantation 1993;55:1361.
4. Mattar T, Kulvinder K, Bartlett RR, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by Leflunomide. FEBS Lett 1993;334:161.
5. Schorlemmer HU, Seiler FR, Bartlett RR. Prolongation of allogeneic transplanted skin grafts and induction of tolerance by Leflunomide, a new immunosuppressive isoaxol derivative. Transplant Proc 1993;25:763.
6. Küchle CCA, Thoenes GH, Langer KH, et al. Prevention of kidney and skin graft rejection in rats by Leflunomide, a new immunomodulatory agent. Transplant Proc 1991,23:1083.
7. Williams JW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation: Control of rejection and alloanti-body production, reversal of acute rejection and interaction with cyclosporine. Transplantation 1994;57:1223.
8. Xiao F, Chong AS, Foster P, et al. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 1994;58:828.
9. McChensney LP, Xiao F, Sankary HN, et al. An evaluation of Leflunomide in the canine renal transplantation model. Transplantation 1994;57:1717.
10. Kemp E, Dieperink H, Jensen J, et al. Newer immunosuppressive drugs in concordant xenografting-transplantation of hamster heart to rat. Xenotransplantation 1994; 1:102.
11. Ulrichs K, Kaitschick J, Bartlett RR, et al. Suppression of natural xenophile antibodies with the novel immunomodulating drug Leflunomide. Transplant Proc 1992;24:718.
12. Dias VC, Lucien J, LeGatt DF, Yatscoff RW. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography. Ther Drug Monit 1995;17:84–8.
13. Yatscoff RW, Honcharik N, Lukowski M, et al. Distribution of cyclosporin G (Nva2 cyclosporin) in blood and plasma. Clin Chem 1993;39:213.
14. Yatscoff RW, LeGatt DF, Keenan R, et al. Blood distribution of rapamycin. Transplantation 1993;56:1202.
15. Langman LL, LeGatt DF, Yatscoff RW. Blood distribution of mycophenolic acid. Clin Biochem 1994;27:206.
16. Legg B, Rowland M., Cyclosporine: Measurement of fraction unbound in plasma. J Pharm Pharmacol 1987;39:599.
17. Redgrave TG, Roberts DCK, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 1975;65:42.
18. Rowland M, Tozer TN. Clinical pharmacokinetics. Philadelphia: Lea and Febiger, 1980:190.
19. Evans WE, Schentag JJ, Jusko WJ, Harrison H, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Spokane, WA: Applied Therapeutics Inc., 1986:28.
20. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporine A in the blood. J Pharm Pharmacol 1982;34:715.
21. Nagase K, Iwasaki K, Nozaki K, et al. Distribution and protein binding of FK506 a potent immunosuppressive mac-rolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 1982;34:715.
22. Honcharik N, Fryer J, Yatscoff RW. Pharmacokinetics of rapamycin: single-dose studies in the rabbit. Ther Drug Monit 1992;14:475.
23. Yatscoff RW, Keenan R, LeGatt DF. Single dose pharmacokinetics of the new immunosuppressant RS-61443 in the rabbit. Ther Drug Monit 1993;15:400.
24. Awni WM, Sawchuck RJ. The pharmacokinetics of cyclosporin: I. Single dose and constant rate infusion studies in the rabbit. Drug Metab Dispos 1985; 13:127.